CRSP · Categories · Form 4
CRSP - SEC Form 4 insider transactions
CRISPR Therapeutics AG (CRSP) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for CRSP
- SEC Form 4 filed by Kasinger James R.4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Kulkarni Samarth4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Prasad Raju4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Patel Naimish4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Medical Officer Patel Naimish converted options into 8,125 shares and sold $152,019 worth of shares (3,150 units at $48.26), increasing direct ownership by 61% to 13,143 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Financial Officer Prasad Raju sold $476,278 worth of shares (9,869 units at $48.26), gifted 750 shares and converted options into 16,875 shares, increasing direct ownership by 92% to 13,023 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- General Counsel and Secretary Kasinger James R. converted options into 6,875 shares and sold $166,497 worth of shares (3,450 units at $48.26), increasing direct ownership by 4% to 91,240 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth sold $499,443 worth of shares (10,349 units at $48.26) and converted options into 20,625 shares, increasing direct ownership by 4% to 245,834 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth converted options into 19,250 shares and sold $517,334 worth of shares (9,798 units at $52.80), increasing direct ownership by 4% to 235,558 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- General Counsel and Secretary Kasinger James R. converted options into 5,500 shares and sold $147,840 worth of shares (2,800 units at $52.80), increasing direct ownership by 3% to 87,815 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth converted options into 13,250 shares and sold $366,325 worth of shares (6,967 units at $52.58), increasing direct ownership by 3% to 226,106 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- General Counsel and Secretary Kasinger James R. converted options into 3,825 shares and sold $111,049 worth of shares (2,112 units at $52.58), increasing direct ownership by 2% to 85,115 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Financial Officer Prasad Raju exercised 34,972 shares at a strike of $45.15 and sold $2,104,965 worth of shares (34,972 units at $60.19) (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth sold $5,166,298 worth of shares (90,000 units at $57.40), decreasing direct ownership by 40% to 134,201 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Financial Officer Prasad Raju exercised 29,700 shares at a strike of $44.97 and sold $1,786,636 worth of shares (29,700 units at $60.16) (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Financial Officer Prasad Raju sold $559,549 worth of shares (10,000 units at $55.95), decreasing direct ownership by 60% to 6,767 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth gifted 30,000 shares, decreasing direct ownership by 12% to 224,201 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth converted options into 100,000 shares and sold $3,456,279 worth of shares (50,895 units at $67.91), increasing direct ownership by 24% to 254,201 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- General Counsel and Secretary Kasinger James R. converted options into 2,114 shares and sold $71,662 worth of shares (1,076 units at $66.60), increasing direct ownership by 1% to 83,402 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth converted options into 8,334 shares and sold $282,517 worth of shares (4,242 units at $66.60), increasing direct ownership by 2% to 205,096 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Kulkarni Samarth4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Patel Naimish4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by General Counsel and Secretary Kasinger James R.4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Prasad Raju4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth gifted 6,000 shares, decreasing direct ownership by 3% to 201,004 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth converted options into 25,000 shares and sold $760,660 worth of shares (13,081 units at $58.15), increasing direct ownership by 6% to 207,004 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director George Simeon4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Behbahani Ali4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Morrison Briggs4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Treco Douglas A4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Mahatme Sandesh4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Rommel Christian4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Fleming Harold Edward4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Greene John4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director Fardis Maria4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Director High Katherine A4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Prasad Raju4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Patel Naimish4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Medical Officer Patel Naimish sold $141,316 worth of shares (3,932 units at $35.94) and converted options into 10,000 shares (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Operating Officer Bruno Julianne converted options into 3,750 shares and sold $70,668 worth of shares (1,714 units at $41.23), increasing direct ownership by 24% to 10,544 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth sold $413,578 worth of shares (10,031 units at $41.23) and converted options into 19,688 shares, increasing direct ownership by 5% to 195,085 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- General Counsel and Secretary Kasinger James R. converted options into 6,250 shares and sold $131,318 worth of shares (3,185 units at $41.23), increasing direct ownership by 4% to 81,729 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Financial Officer Prasad Raju converted options into 6,250 shares and sold $90,582 worth of shares (2,197 units at $41.23), increasing direct ownership by 32% to 16,767 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Kulkarni Samarth4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Operating Officer Bruno Julianne4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Financial Officer Prasad Raju converted options into 10,000 shares and sold $157,252 worth of shares (3,762 units at $41.80), increasing direct ownership by 96% to 12,714 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Patel Naimish4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by General Counsel and Secretary Kasinger James R.4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Operating Officer Bruno Julianne converted options into 2,834 shares and sold $59,050 worth of shares (1,388 units at $42.54), increasing direct ownership by 20% to 8,508 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- General Counsel and Secretary Kasinger James R. converted options into 7,750 shares and sold $169,242 worth of shares (3,966 units at $42.67), increasing direct ownership by 5% to 78,664 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth converted options into 28,250 shares and sold $616,348 worth of shares (14,435 units at $42.70), increasing direct ownership by 8% to 185,428 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth sold $1,013,564 worth of shares (18,360 units at $55.20), decreasing direct ownership by 10% to 171,613 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- General Counsel and Secretary Kasinger James R. converted options into 23,825 shares and sold $619,492 worth of shares (11,542 units at $53.67), increasing direct ownership by 20% to 74,880 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth converted options into 13,250 shares and sold $1,006,580 worth of shares (18,568 units at $54.21), decreasing direct ownership by 3% to 189,973 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Operating Officer Bruno Julianne converted options into 650 shares and sold $17,582 worth of shares (333 units at $52.80), increasing direct ownership by 5% to 7,062 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth exercised 13,751 shares at a strike of $16.21, increasing direct ownership by 8% to 195,291 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth sold $826,564 worth of shares (15,000 units at $55.10), decreasing direct ownership by 8% to 181,540 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- Chief Executive Officer Kulkarni Samarth sold $1,668,678 worth of shares (30,000 units at $55.62), decreasing direct ownership by 13% to 196,540 units (SEC Form 4)4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Operating Officer Bruno Julianne4 - CRISPR Therapeutics AG (0001674416) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Kulkarni Samarth4 - CRISPR Therapeutics AG (0001674416) (Issuer)